BackArtiva Biotherapeutics Overview
Artiva Biotherapeutics Inc

Artiva Biotherapeutics P/E Ratio

Latest P/E ratio for Artiva Biotherapeutics: -3.4 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-3.40

P/E Ratio

-3.40

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

Average P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Artiva Biotherapeutics (ARTV) FAQ

Artiva Biotherapeutics (ARTV) currently reports a P/E ratio of -3.4. That is below the sector sector average of 47.3. Use the charts on this page to explore Artiva Biotherapeutics's P/E ratio history and peer comparisons.

Artiva Biotherapeutics's P/E ratio of -3.4 is lower than the its sector sector average of 47.3. That is roughly 107.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Artiva Biotherapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -3.4, ARTV can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -3.4, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 47.3. From there, open related valuation or income-statement pages for Artiva Biotherapeutics, and consider following ARTV for alerts when major investors trade the stock.